Algeta positive again with Alpharadin, in breast cancer bone metastases
This article was originally published in Scrip
Executive Summary
Norway's Algeta has reported positive preliminary bone marker results in a Phase IIa study evaluating its lead product candidate, the anticancer, Alpharadin (radium-223 chloride), in breast cancer patients with bone metastases.